<code id='59D43FF4E8'></code><style id='59D43FF4E8'></style>
    • <acronym id='59D43FF4E8'></acronym>
      <center id='59D43FF4E8'><center id='59D43FF4E8'><tfoot id='59D43FF4E8'></tfoot></center><abbr id='59D43FF4E8'><dir id='59D43FF4E8'><tfoot id='59D43FF4E8'></tfoot><noframes id='59D43FF4E8'>

    • <optgroup id='59D43FF4E8'><strike id='59D43FF4E8'><sup id='59D43FF4E8'></sup></strike><code id='59D43FF4E8'></code></optgroup>
        1. <b id='59D43FF4E8'><label id='59D43FF4E8'><select id='59D43FF4E8'><dt id='59D43FF4E8'><span id='59D43FF4E8'></span></dt></select></label></b><u id='59D43FF4E8'></u>
          <i id='59D43FF4E8'><strike id='59D43FF4E8'><tt id='59D43FF4E8'><pre id='59D43FF4E8'></pre></tt></strike></i>

          Home / fashion / hotspot

          hotspot


          hotspot

          author:leisure time    Page View:5946
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In